Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter P Toth

Showing results (1-10 of 425) with videos related to

Pageof 43
Sort By:
Journal of Clinical Lipidology|February 5, 2011
Making a case for quantitative assessment of cardiovascular riskPeter P Toth
European Journal of Preventive Cardiology|May 12, 2025
Despite More Aggressive Lipid Lowering Guidelines Worldwide, the Majority of High Risk Patients Remain UndertreatedPeter P Toth
The Journal of Family Practice|January 6, 2010
An Urgent Matter. Identifying Your Patients' Cardiovascular Risk and Improving Their Outcomes. IntroductionPeter P Toth
The American Journal of Cardiology|November 18, 2005
High-density lipoprotein as a therapeutic target: clinical evidence and treatment strategiesPeter P Toth
Circulation Research|June 25, 2016
PCSK9 and Lipoprotein(a): The Plot ThickensPeter P Toth
American Journal of Preventive Cardiology|July 30, 2021
Identification and treatment of those most at risk for premature atherosclerotic cardiovascular disease: We just cannot seem to get it rightPeter P Toth
The American Journal of Cardiology|September 14, 2016
Novel Therapies for Low-Density Lipoprotein Cholesterol ReductionPeter P Toth
Postgraduate Medicine|January 31, 2009
The potential role of prasugrel in secondary prevention of ischemic events in patients with acute coronary syndromesPeter P Toth
Current Atherosclerosis Reports|November 16, 2007
The COURAGE Trial: establishing the therapeutic legitimacy of aggressive risk factor management in patients with stable coronary artery disease as an alternative to percutaneous coronary interventionPeter P Toth
Endocrinology and Metabolism Clinics of North America|February 17, 2009
Novel therapies for increasing serum levels of HDLPeter P Toth
Pageof 43

Showing results (1-10 of 425) with videos related to

Sort By:
Pageof 43
Journal of Clinical Lipidology|February 5, 2011
Making a case for quantitative assessment of cardiovascular riskPeter P Toth
European Journal of Preventive Cardiology|May 12, 2025
Despite More Aggressive Lipid Lowering Guidelines Worldwide, the Majority of High Risk Patients Remain UndertreatedPeter P Toth
The Journal of Family Practice|January 6, 2010
An Urgent Matter. Identifying Your Patients' Cardiovascular Risk and Improving Their Outcomes. IntroductionPeter P Toth
The American Journal of Cardiology|November 18, 2005
High-density lipoprotein as a therapeutic target: clinical evidence and treatment strategiesPeter P Toth
Circulation Research|June 25, 2016
PCSK9 and Lipoprotein(a): The Plot ThickensPeter P Toth
American Journal of Preventive Cardiology|July 30, 2021
Identification and treatment of those most at risk for premature atherosclerotic cardiovascular disease: We just cannot seem to get it rightPeter P Toth
The American Journal of Cardiology|September 14, 2016
Novel Therapies for Low-Density Lipoprotein Cholesterol ReductionPeter P Toth
Postgraduate Medicine|January 31, 2009
The potential role of prasugrel in secondary prevention of ischemic events in patients with acute coronary syndromesPeter P Toth
Current Atherosclerosis Reports|November 16, 2007
The COURAGE Trial: establishing the therapeutic legitimacy of aggressive risk factor management in patients with stable coronary artery disease as an alternative to percutaneous coronary interventionPeter P Toth
Endocrinology and Metabolism Clinics of North America|February 17, 2009
Novel therapies for increasing serum levels of HDLPeter P Toth
Pageof 43